Indivior (NASDAQ:INDV – Get Free Report) was downgraded by stock analysts at Zacks Research from a “strong-buy” rating to a “hold” rating in a report issued on Monday,Zacks.com reports.
Several other equities research analysts also recently commented on the stock. Barclays assumed coverage on shares of Indivior in a research note on Thursday, June 18th. They issued an “overweight” rating and a $46.00 target price for the company. Weiss Ratings upgraded Indivior from a “hold (c)” rating to a “hold (c+)” rating in a report on Tuesday, June 23rd. Six analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $40.29.
View Our Latest Research Report on Indivior
Indivior Stock Down 0.6%
Indivior (NASDAQ:INDV – Get Free Report) last announced its quarterly earnings data on Tuesday, March 31st. The company reported $0.96 earnings per share (EPS) for the quarter. Indivior had a net margin of 19.44% and a negative return on equity of 219.26%. The firm had revenue of $317.00 million for the quarter. Sell-side analysts predict that Indivior will post 4.05 earnings per share for the current fiscal year.
Insider Activity at Indivior
In other news, CFO Ryan Preblick sold 36,000 shares of the firm’s stock in a transaction dated Monday, June 8th. The stock was sold at an average price of $37.70, for a total value of $1,357,200.00. Following the completion of the transaction, the chief financial officer owned 284,751 shares in the company, valued at $10,735,112.70. This trade represents a 11.22% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.74% of the stock is currently owned by corporate insiders.
Institutional Investors Weigh In On Indivior
Large investors have recently made changes to their positions in the stock. Caitong International Asset Management Co. Ltd increased its stake in shares of Indivior by 72.7% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,093 shares of the company’s stock worth $39,000 after purchasing an additional 460 shares during the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al lifted its position in Indivior by 3.4% during the fourth quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 21,200 shares of the company’s stock worth $761,000 after acquiring an additional 700 shares during the last quarter. Blue Trust Inc. grew its position in shares of Indivior by 17.8% in the fourth quarter. Blue Trust Inc. now owns 4,859 shares of the company’s stock valued at $176,000 after purchasing an additional 733 shares during the last quarter. Harbor Capital Advisors Inc. increased its stake in shares of Indivior by 309.9% during the fourth quarter. Harbor Capital Advisors Inc. now owns 1,033 shares of the company’s stock worth $37,000 after purchasing an additional 781 shares during the period. Finally, Salomon & Ludwin LLC acquired a new stake in Indivior during the 4th quarter worth approximately $30,000. Institutional investors and hedge funds own 60.33% of the company’s stock.
Indivior Company Profile
Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.
Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.
Featured Articles
- Five stocks we like better than Indivior
- Burger King’s Turnaround Is Putting Restaurant Brands Back in Focus
- Short Squeeze Alert—Moderna Stock Surges on New Strategy
- NextEra’s Dominion Deal Could Put It at the Center of the AI Power Race
- Amazon Could Be About to Reap the Rewards of a Software Spending Boom
Receive News & Ratings for Indivior Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior and related companies with MarketBeat.com's FREE daily email newsletter.
